Every material Form 8-K Beyond Air, Inc. has filed with the SEC since August 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Beyond Air, Inc. said preliminary, unaudited revenue for the quarter ended September 30, 2026 was about $2.3 million, up about 30% from the prior quarter and 27% from the same quarter last year. The company reaffirmed its revenue guidance of $8 million for calendar 2026 and $16 million to $18 million for calendar 2027, but the preliminary figure may differ materially from final results due in November 2026.
Preliminary Q3 2026 revenue of about $2.3 million, unaudited and not reviewed by the auditor
Calendar 2026 revenue guidance of $8 million reaffirmed, excluding the second-generation LungFit PH system
Calendar 2027 guidance of $16 million to $18 million reaffirmed, including the second-generation system pending FDA approval
Beyond Air, Inc. entered into a formal employment agreement with Chief Executive Officer Robert Goodman on September 23, 2026, after he had served in the role since March 27, 2026 without a written agreement. The filing also discloses that Chief Financial Officer Daniel Moorhead's base salary was raised from $325,000 to $463,000, effective September 23, 2026.
CEO Robert Goodman's employment agreement, dated September 23, 2026, sets a base salary of not less than $650,000 and a target annual bonus of 60% of salary.
If terminated without Cause or for Good Reason, Goodman receives 12 months of base salary continuation; within three months before to 12 months after a Change in Control, he receives a lump sum of 24 months of salary.
CFO Daniel Moorhead's base salary increased from $325,000 to $463,000, effective September 23, 2026.
Beyond Air reported revenue of $1.8 million for the quarter ended June 30, 2026, unchanged from the prior-year quarter, while its net loss attributable to common stockholders widened to $7.9 million from $7.7 million. The company reaffirmed its calendar 2026 revenue guidance of $8 million and its 2027 guidance of $16-$18 million, and disclosed a financing of up to $30.1 million, including $10.2 million in upfront gross proceeds, which it said will fund international expansion and a U.S. launch pending FDA approval.
Revenue was $1.8 million in both the quarter ended June 30, 2026 and the same quarter of 2025; gross margin rose to 13% from 9%.
Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, versus $7.7 million, or $30.67 per share, a year earlier; per-share figures reflect a one-for-twenty stock split in July 2026.
Cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million at June 30, 2026, before the financing of up to $30.1 million announced after quarter-end.
The company said it regained compliance with Nasdaq's minimum bid price requirement and that the FDA review of the second-generation LungFit PH PMA supplement is pending, with approval expected in the second half of calendar 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Beyond Air, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →